Salubris layouts the global industrial chain precisely and the global business has covered more than 38 countries and regions, including China, USA, Germany, France and Japan.
Salubris will focus on patients and pursue the improvement of products and customers satisfaction. With the differentiated competitive advantages, Salubris will gradually become a China-based international innovative pharmaceutical enterprise.
We are looking forward to long and successful partnership with leading academic institutions, biotech companies and pharma companies in the areas of cardiovascular, metabolic disease and cancer. We are seeking cooperation for both pre-clinical and clinical development.
Contact us at: email@example.com